Current Headlines

  1. Response To Gene-Targeted Drugs Depends On Cancer Type

    Cancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumour type of the patient, new research reveals.

  2. UC San Diego Chemists Take Aim At Drug Predictions

    As many American consumers know, “pharma” means the big business of drug therapy. According to the U.S. National Library of Medicine, drug discovery is no longer a “target-and-mechanism-agnostic approach,” rooted in ethnobotanical information and infused with “serendipity.” Instead, drug discovery has grown into a hypothesis-driven, target-based approach

  3. LifeMax Receives Orphan Drug Designation From The United States Food & Drug Administration For LM-030 For The Treatment Of Netherton Syndrome

    LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on treating rare diseases with few or no therapeutic options, recently announced that the Food & Drug Administration (FDA) granted orphan drug designation to LM-030, an investigational therapy licensed from Novartis and ready to enter into pivotal clinical trials for the treatment of Netherton Syndrome

  4. PeptiDream Announces New Peptide Drug Conjugate (‘PDC’) Collaboration Agreement With Novartis

    PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced recently a new Peptide Drug Conjugate “PDC” collaboration agreement with Swiss-based Novartis (“Novartis”)

  5. Knight Announces Filing Of New Drug Submission For Ibsrela™ In Canada

    Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Ibsrela™ (tenapanor) has been accepted for review by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C). Knight and Ardelyx Inc. (NASDAQ: ARDX) entered into a license agreement in March 2018 granting Knight the exclusive right to commercialize tenapanor in Canada

  6. Rafael Pharmaceuticals Enters Into Out-Licensing Agreement With Ono Pharmaceutical To Accelerate Clinical Development And Commercialization Of Cancer Drug Candidate CPI-613® (Devimistat) In Japan And Other Asian Countries

    Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has entered into an out-licensing agreement with Ono Pharmaceutical Co., Ltd. (“Ono”), a pharmaceutical company committed to creating innovative medicines

  7. C4X Discovery And PhoreMost Collaboration To Accelerate Parkinson’s Disease Drug Discovery Pipeline

    C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s Disease, will combine both company’s technology platforms

  8. Gilead And Carna Biosciences Announce Research And Development Collaboration To Develop Novel Immuno-Oncology Therapies

    Gilead Sciences, Inc. and Carna Biosciences Inc recently announced that the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform

  9. Atomwise And Enamine To Advance Pediatric Oncology With The World’s First And Largest Ten Billion Compound Virtual Screen

    Atomwise, Inc. recently announced the launch of a 10 billion compound AI-powered virtual drug screening initiative, the 10-to-the-10 program, in collaboration with Enamine Ltd., the world’s largest chemical supplier

  10. Minerva Biotechnologies Announces FDA Acceptance Of IND Application For huMNC2-CAR44 T Cells To Treat Metastatic Breast Cancer

    Minerva Biotechnologies, a biopharmaceutical company focused on developing immunotherapies for cancer and cellular therapies in regenerative medicine, announced recently that the U.S. FDA (Food and Drug Administration) has approved their IND (Investigational New Drug) application to conduct clinical trials with huMNC2-CAR44, an autologous CAR T cell therapy for solid tumors